The mitochondrial gambit: Re-evaluating Antimycin A as a multi-pronged anti-cancer agent

Area of Science:

• Mitochondrial Metabolism
• Cancer Therapeutics
• Oncology

Background:

• Malignancy heavily relies on mitochondrial metabolism, making mitochondria a key therapeutic target.
• Antimycin A (AMA) is a mitochondrial complex III inhibitor with significant anti-cancer potential.
• Understanding AMA's multi-pronged mechanisms is crucial for developing novel cancer treatments.

Purpose of the Study:

• To provide a comprehensive analysis of Antimycin A (AMA) as a multi-pronged anti-cancer agent.
• To explore AMA's canonical and non-canonical mechanisms against cancer resilience.
• To evaluate strategies for developing safer, clinically viable AMA analogues.

Main Methods:

• Review of literature on Antimycin A's effects on mitochondrial metabolism.
• Analysis of AMA's impact on oxidative phosphorylation (OXPHOS), ATP levels, ROS production, and apoptosis.
• Investigation of AMA's non-canonical functions, including BH3 mimetic activity, c-Myc degradation, and Wnt/β-catenin signaling inhibition.

Main Results:

• AMA disrupts OXPHOS, leading to ATP depletion, ROS surges, and apoptosis.
• AMA inhibits Bcl-xL and promotes ROS-mediated c-Myc degradation.
• AMA targets chemoresistant cancer stem cells (CSCs) by suppressing Wnt/β-catenin signaling.

Conclusions:

• Antimycin A exhibits potent anti-neoplastic activities through diverse mechanisms.
• AMA's systemic toxicity presents pharmacological limitations.
• AMA serves as a lead compound for developing novel mitochondria-targeted cancer therapies.